Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Interferon and Thalidomide in Metastatic Melanoma
NCT00238329Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jan 2001
- Primary completion
- Dec 2005
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b, thalidomide in melanoma, sponsored by Barbara Ann Karmanos Cancer Institute. Started Jan 2001; status: completed.
02
Drugs
peginterferon alfa-2bthalidomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00238329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238329.